These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 10890777)

  • 1. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.
    Wagner JA; Messner AH; Moran ML; Daifuku R; Kouyama K; Desch JK; Manley S; Norbash AM; Conrad CK; Friborg S; Reynolds T; Guggino WB; Moss RB; Carter BJ; Wine JJ; Flotte TR; Gardner P
    Laryngoscope; 1999 Feb; 109(2 Pt 1):266-74. PubMed ID: 10890777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies.
    Wagner JA; Nepomuceno IB; Messner AH; Moran ML; Batson EP; Dimiceli S; Brown BW; Desch JK; Norbash AM; Conrad CK; Guggino WB; Flotte TR; Wine JJ; Carter BJ; Reynolds TC; Moss RB; Gardner P
    Hum Gene Ther; 2002 Jul; 13(11):1349-59. PubMed ID: 12162817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung.
    Conrad CK; Allen SS; Afione SA; Reynolds TC; Beck SE; Fee-Maki M; Barrazza-Ortiz X; Adams R; Askin FB; Carter BJ; Guggino WB; Flotte TR
    Gene Ther; 1996 Aug; 3(8):658-68. PubMed ID: 8854091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus.
    Wagner JA; Reynolds T; Moran ML; Moss RB; Wine JJ; Flotte TR; Gardner P
    Lancet; 1998 Jun; 351(9117):1702-3. PubMed ID: 9734891
    [No Abstract]   [Full Text] [Related]  

  • 5. Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials in patients with antrostomies.
    Wagner JA; Nepomuceno IB; Shah N; Messner AH; Moran ML; Norbash AM; Moss RB; Wine JJ; Gardner P
    J Gene Med; 1999; 1(1):13-21. PubMed ID: 10738581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid-DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis.
    Knowles MR; Noone PG; Hohneker K; Johnson LG; Boucher RC; Efthimiou J; Crawford C; Brown R; Schwartzbach C; Pearlman R
    Hum Gene Ther; 1998 Jan; 9(2):249-69. PubMed ID: 9472784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease.
    Aitken ML; Moss RB; Waltz DA; Dovey ME; Tonelli MR; McNamara SC; Gibson RL; Ramsey BW; Carter BJ; Reynolds TC
    Hum Gene Ther; 2001 Oct; 12(15):1907-16. PubMed ID: 11589832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel AAV-mediated Gene Delivery System Corrects CFTR Function in Pigs.
    Cooney AL; Thornell IM; Singh BK; Shah VS; Stoltz DA; McCray PB; Zabner J; Sinn PL
    Am J Respir Cell Mol Biol; 2019 Dec; 61(6):747-754. PubMed ID: 31184507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.
    Moss RB; Rodman D; Spencer LT; Aitken ML; Zeitlin PL; Waltz D; Milla C; Brody AS; Clancy JP; Ramsey B; Hamblett N; Heald AE
    Chest; 2004 Feb; 125(2):509-21. PubMed ID: 14769732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector.
    Flotte TR; Afione SA; Conrad C; McGrath SA; Solow R; Oka H; Zeitlin PL; Guggino WB; Carter BJ
    Proc Natl Acad Sci U S A; 1993 Nov; 90(22):10613-7. PubMed ID: 7504271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technology evaluation: AAV-CFTR vector, targeted genetics.
    Tebbutt SJ
    Curr Opin Mol Ther; 1999 Aug; 1(4):524-9. PubMed ID: 11713770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study.
    Flotte TR; Zeitlin PL; Reynolds TC; Heald AE; Pedersen P; Beck S; Conrad CK; Brass-Ernst L; Humphries M; Sullivan K; Wetzel R; Taylor G; Carter BJ; Guggino WB
    Hum Gene Ther; 2003 Jul; 14(11):1079-88. PubMed ID: 12885347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy in cystic fibrosis.
    Flotte TR; Laube BL
    Chest; 2001 Sep; 120(3 Suppl):124S-131S. PubMed ID: 11555567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis.
    Knowles MR; Hohneker KW; Zhou Z; Olsen JC; Noah TL; Hu PC; Leigh MW; Engelhardt JF; Edwards LJ; Jones KR
    N Engl J Med; 1995 Sep; 333(13):823-31. PubMed ID: 7544439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis.
    Porteous DJ; Dorin JR; McLachlan G; Davidson-Smith H; Davidson H; Stevenson BJ; Carothers AD; Wallace WA; Moralee S; Hoenes C; Kallmeyer G; Michaelis U; Naujoks K; Ho LP; Samways JM; Imrie M; Greening AP; Innes JA
    Gene Ther; 1997 Mar; 4(3):210-8. PubMed ID: 9135734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus 5-fiber 35 chimeric vector mediates efficient apical correction of the cystic fibrosis transmembrane conductance regulator defect in cystic fibrosis primary airway epithelia.
    Granio O; Ashbourne Excoffon KJ; Henning P; Melin P; Norez C; Gonzalez G; Karp PH; Magnusson MK; Habib N; Lindholm L; Becq F; Boulanger P; Zabner J; Hong SS
    Hum Gene Ther; 2010 Mar; 21(3):251-69. PubMed ID: 19788389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.
    Moss RB; Milla C; Colombo J; Accurso F; Zeitlin PL; Clancy JP; Spencer LT; Pilewski J; Waltz DA; Dorkin HL; Ferkol T; Pian M; Ramsey B; Carter BJ; Martin DB; Heald AE
    Hum Gene Ther; 2007 Aug; 18(8):726-32. PubMed ID: 17685853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications.
    Joseph PM; O'Sullivan BP; Lapey A; Dorkin H; Oren J; Balfour R; Perricone MA; Rosenberg M; Wadsworth SC; Smith AE; St George JA; Meeker DP
    Hum Gene Ther; 2001 Jul; 12(11):1369-82. PubMed ID: 11485629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic fibrosis transmembrane conductance regulator with a shortened R domain rescues the intestinal phenotype of CFTR-/- mice.
    Ostedgaard LS; Meyerholz DK; Vermeer DW; Karp PH; Schneider L; Sigmund CD; Welsh MJ
    Proc Natl Acad Sci U S A; 2011 Feb; 108(7):2921-6. PubMed ID: 21285372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line.
    Kearns WG; Afione SA; Fulmer SB; Pang MC; Erikson D; Egan M; Landrum MJ; Flotte TR; Cutting GR
    Gene Ther; 1996 Sep; 3(9):748-55. PubMed ID: 8875221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.